pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. These are particularly important in the progression of certain blood cancers.

Development 52

Development Drugs Clinical Development Antibody 52

XTalks

FEBRUARY 27, 2024

Melanoma is a type of skin cancer often caused by exposure to ultraviolet light, such as that from sunlight or indoor tanning. Despite accounting for only about one percent of all skin cancers, melanomas make up a significant proportion of cancer-related deaths. The cost is the highest of any cell-based cancer drug in the US.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Delveinsight

FEBRUARY 9, 2021

Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal. Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod.

FDA Approval 52

FDA Approval Marketing Research Protein 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MARCH 7, 2022

Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports. The AI-designed protein was developed at the UW Medicine Institute for Protein Design (IPD) under the leadership of David Baker, also a professor of biochemistry and head of the IPD.

Protein 52

Protein Gene Genome Genomics 52

pharmaphorum

JANUARY 21, 2022

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance.

Medicine 52

Medicine Marketing Manufacturing Production 52

XTalks

FEBRUARY 11, 2021

Much of the fundamental groundwork for genetics and genomic research was laid in the 20 th century, with significant contributions from women scientists, some of whom worked during times when acceptance of female researchers was not widespread. Here is a profile of some of those brilliant women who helped shape genetics research.

Genetics 119

Genetics DNA Genome Genomics 119

The Pharma Data

MARCH 20, 2021

The Weatherall Institute of Molecular. Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. Highlight #1 Dr. Neil Ashley, the Single-Cell Core Facility Manager at the Weatherall Institute of Molecular Medicine (WIMM) in Oxford, U.K., presented the.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Biobanking 103

Biobanking Clinical Trials Clinical Trials Trials 103